A twenty-year-old male was diagnosed with common variable immunodecifiency (CVID) according to decreased blood level of immunoglobulins along with a history of recurrent sinopulmonary infection since early childhood, no response to prior vaccination, and the absence of all other defined immunodeficiency. Eleven months after the initiation of intravenous immunoglobulin replacement, he presented with petechiae on both lower legs for three weeks. Bone marrow exam was conducted as pancytopenia was not resolved over a month and severe aplastic anemia was diagnosed. Allogenic stem cell transplantation (Allo-SCT) with reduced intensity conditioning (RIC) enabled both a clinical resolution from propensity to infection with an appropriate production of immunoglobulins and a successful rescue of hematopoiesis. This report suggests that Allo-SCT using RIC is a potentially curable option in patients with CVID complicated by SAA if adequate efforts to minimize Allo-SCT-related complications are accompanied.
INTRODUCTION
Common variable immunodeficiency (CVID) is a heterogeneous group of primary immune disorders presented with a defective immunoglobulin production with impaired immune response. Although there is no perfect consensus on the diagnostic criteria of CVID, it is usually defined when a patient has (1) markedly reduced serum immunoglobulin G (IgG) with low levels of immunoglobulin A (IgA), and/or immunoglobulin M (IgM), (2) poor or absent antibody response to infection or immunization, and (3) an absence of any other immunodeficiency state or secondary cause of hypogammoglobulinemia [1] . Although the number of B-cells in patients with CVID is usually normal, the B-cells have impaired immune function due to dysfunction of toll-like receptors on B-cells and the scarcity of isotype-switched memory B-cells [2] . In addition, T-cell abnormalities such as a low CD4/CD8 ratio were found in a subset of CVID patients and it is correlated with the severity of clinical manifestations [3] .
Recurrent infection is the most common manifestation of patients with CVID and sinopulmonary infection is observed in the majority of patients [1, 4] . Patients may also suffer from autoimmune disease, lymphocytic organ infiltration such as granuloma or splenomegaly, and malignancies [4] . Intravenous immunoglobulin (IVIg) replacement can dramatically reduce the incidence of death from bacterial infection [5] . However, IVIg replacement is not a curative approach and it is unclear that the replacement protects against granulomatous disease or cancers [5] . Here, we report a case of CVID followed by severe aplastic anemia (SAA) that successfully achieved resolution from propensity to infection as well as normal hematopoiesis by reduced intensity conditioning (RIC) allograft.
CASE REPORT
A twenty-year-old male patient presented with right chest wall pain for a week. He had developed recurrent sinopulmonary infection ever since he was three months old. When he was six years old, he suffered from severe pneumonia after vaccination for in-fluenza and was hospitalized for a month. Thereafter he would often develop sinopulmonary infection at the change of seasons. The vital signs were: 100/60 mm Hg for blood pressure, 100/min for heart rate, 18/min for respiratory rate, and 37.8°C for body tem- http://jsms.sch.ac.kr +1 and 10 mg/m 2 on days +3, +6, and +11) was administered in combination with intravenous tacrolimus (0.03 mg/kg/day from day -2 and doses were adjusted according to blood level and later changed to oral route). An engraftment was achieved successfully on day +12 and he was discharged from hospital on day +21. Follow-up BME (Fig. 2) and post-transplant short tandem repeat study performed on day +30 showed normal active trilineage hematopoiesis with complete donor chimerism. Grade 1 acute GVHD was developed on day +75 but it was confined to the skin and disappeared soon by topical steroids lotion and did not reemerge thereafter. Serum Ig G levels were normalized without IVIg administration after Allo-SCT. Immunosuppression was discontinued on day +120 and the patient has now maintained normal CBC and complete chimerism without any significant episode of respiratory infection for 17 months (Fig. 3) .
DISCUSSION
Because Allo-SCT provides a new establishment of immune system derived from donor stem cells, it has been evaluated as a treatment option in primary immunodeficiencies [6] . The role of Allo-SCT in pediatric patients with severe combined immunodeficiency is well known and now the survival rate for Allo-SCT from matched sibling donor is probably over 90% [6] . Allo-SCT has also been applied to various congenital, early onset diseases of primary immunodeficiency such as Wiskott-Aldrich syndrome, congenital T-cell defects, phagocytic cell disorders, and hemophagocytic syndromes [6] .
The majority of patients with CVID are diagnosed between ages of 20 and 45 [4] . This relatively late time of diagnosis resulted in a slightly different approach to treating CVID patients from those with early onset primary immunodeficiencies. IVIg replacement,
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Fig. 2. (A) Findings of bone marrow biopsy (H&E, × 200). (B) Chromosomal analysis (46,XX,14ps+,21ps+[30]
; 14ps+ and 21ps+ were normal heteromorphism) conducted 4 months after allogenic stem cell transplantation. patients with serious complications of CVID [8] . They reported that one of them had SAA and was indicative of Allo-SCT. The patient had a matched unrelated donor and received Allo-SCT with RIC using busulfan and melphalan [8] . However, detailed information including doses of conditioning regimen, GVHD prophylaxis, or follow-up duration after Allo-SCT was not provided in the report [8] . Although there was a report that some cases of CVID may be due to a mutation in the SBDS gene of Shwachman-Diamond syndrome [9] , our patient had a feature of acquired SAA.
However, we believe that it is natural to regard SAA as a kind of 'immune disorders' that can be observed in patients with CVID.
The multicenter analysis from EBMT reported that overall mortality was 52% and severe GVHD (32%) was a major affecting factor contributing to the relatively high mortality, possibly because for most patients only a single agent was used for GVHD prophylaxis [8] . High incidence of GVHD might be related to the increased serum tumor necrosis factor levels which are also observed in patients with CVID [10] . This report gives us insights into Allo-SCT for the treatment of CVID, including caution for GVHD. However, it was a retrospective analysis and the time of Allo-SCT ranges from 1993 to 2012 [8] , suggesting that actual outcome might be better nowadays using improved GVHD prophylaxis and other supportive care.
In summary, Allo-SCT is a potentially curable option in patients with CVID complicated by SAA because both recovery of hematopoiesis and reconstitution of the immune system can be achieved by Allo-SCT if adequate efforts to minimize Allo-SCT-related complications accompany the treatment.
